Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

1.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.1K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

407
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
407
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

530
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
530
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

904
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
904
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

831
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
831

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk prediction of <i>Helicobacter pylori</i> strains across Correa's cascade via intelligent analysis of genome-wide SNPs.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Molecular Mechanisms of β-Lactam Resistance and Its Contribution to Multidrug Resistance in Helicobacter pylori.

The Journal of infectious diseases·2026
Same author

Setting higher standards for reports of microbial species in human cancers.

Nature cancer·2026
Same author

Corrigendum to "Enhanced LRP8 expression induced by Helicobacter pylori drives gastric cancer progression by facilitating β-Catenin nuclear translocation". [J. Adv. Res. 69 (2025) 299-312].

Journal of advanced research·2025
Same author

Multi-omics Analysis Reveals How Intratumoral Bacteria Shape the Immune Microenvironment in Gastric Cancer.

Genomics, proteomics & bioinformatics·2025
Same author

Antimicrobial Resistance Patterns of Clinical Helicobacter pylori Isolates From Gastric Cancer Patients.

The Journal of infectious diseases·2025

Related Experiment Video

Updated: Jan 10, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

720

Rifabutin-Containing Therapy for Helicobacter pylori Eradication: A Review.

Jun-Peng Zhou1,2, Tian-Kuo Yang3, Juan Li4,5

  • 1Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

The Journal of Infectious Diseases
|November 20, 2025
PubMed
Summary

Rifabutin shows promise for eradicating Helicobacter pylori, especially with rising antibiotic resistance. Further trials are needed to optimize rifabutin regimens for effective H. pylori treatment.

Keywords:
Helicobacter pyloriantibiotic resistanceeradication therapiesrescue therapyrifabutin

More Related Videos

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

4.3K
Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology
03:33

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology

Published on: May 23, 2025

715

Related Experiment Videos

Last Updated: Jan 10, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

720
Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

4.3K
Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology
03:33

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology

Published on: May 23, 2025

715

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Pharmacology

Background:

  • Helicobacter pylori infection is a major cause of gastritis, ulcers, and gastric cancer.
  • Increasing antibiotic resistance is leading to higher H. pylori eradication failure rates.
  • Rifabutin offers potential as an alternative H. pylori treatment due to its efficacy and stability.

Purpose of the Study:

  • To review the efficacy and safety of rifabutin-containing H. pylori eradication regimens.
  • To analyze factors influencing rifabutin treatment outcomes and patient compliance.
  • To discuss rifabutin resistance mechanisms and future research directions.

Main Methods:

  • Systematic review of studies on rifabutin-based H. pylori eradication.
  • Analysis of rifabutin dosage, drug combinations, therapy duration, and demographic factors.
  • Review of literature on rifabutin resistance in H. pylori.

Main Results:

  • Rifabutin-containing regimens demonstrate potential for H. pylori eradication.
  • Factors like dosage, combination therapy, and duration impact efficacy.
  • Rifabutin resistance mechanisms and susceptibility testing require further investigation.

Conclusions:

  • Rifabutin is a promising option for H. pylori eradication, particularly in cases of antibiotic resistance.
  • Optimization of rifabutin regimens, including dosing and duration, is crucial.
  • Large-scale trials are needed to establish optimal rifabutin-based therapies and standardized resistance testing.